Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ wholly-owned subsidiary – Sun Pharma Laboratories has received approval from Board of Directors for an investment of Rs 3,000 crore for setting up a greenfield formulations manufacturing facility in Madhya Pradesh.

Earlier, the company had launched its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.